Matches in SemOpenAlex for { <https://semopenalex.org/work/W3030609620> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W3030609620 endingPage "649" @default.
- W3030609620 startingPage "645" @default.
- W3030609620 abstract "Objective To evaluate effects of autologous stem cell transplantation (ASCT) on new diagnosed multiple myeloma (MM) patients.Methods 42 newly diagnosed MM patients who obtained partial remission (PR) or better and received ASCT were selected.With a median 34.2 months follow-up,therapeutic effects,progression-free survival (PFS) and overall survival (OS) of 42 newly diagnosed patients received ASCT were analyzed.49 patients who obtained PR or better after induction therapy but not received ASCT were selected as control.The differences of these two groups were analyzed and effects of ASCT on new diagnosed MM patients were evaluated.Results Compared with non-ASCT patients,patients received ASCT had longer OS (not reached vs 37.2 months,P =0.000).ASCT could also prolonged PFS of MM patients,but there was not significant difference (33.9 months vs 39.8 months,P =0.133).ASCT could significantly improved PFS of MM patients with DS Ⅲ stage (P =0.009) and ISS Ⅲ stage (P =0.049),however,it could improve PFS of DS Ⅰ /Ⅱ stage and ISS Ⅰ/Ⅱ] stage.ASCT could significantly improve PFS of patients obtained complete remission (CR) (P =0.016),however,it had not significant effect on patients obtained very good PR (VGPR) or PR after induction therapy.ASCT could significantly improved OS of patients aged ≤55 years old (P =0.039) and ＞ 55 years old (P =0.000).ASCT could significantly improved OS of MM patients with ISS Ⅰ /Ⅱ stage (P =0.003),ISS Ⅲ stage (P =0.012) and DS Ⅲ stage (P =0.000),however,it had not significant effect on patients with DSⅠ/ Ⅱ] stage (P =0.446).After induction therapy,ASCT could further improved OS of patients obtained CR (P =0.004) or VGPR/PR (P =0.004).Conclusion ASCT could significantly improve OS of new diagnosed MM patients and could make MM patients obtaine more benefits who are at high risk at age and stages.Key words: Multiple myeloma; Autologous stem cell transplantation; Overall survival" @default.
- W3030609620 created "2020-06-05" @default.
- W3030609620 creator A5005131686 @default.
- W3030609620 creator A5010738973 @default.
- W3030609620 creator A5015870868 @default.
- W3030609620 creator A5018889104 @default.
- W3030609620 creator A5031186378 @default.
- W3030609620 creator A5036519850 @default.
- W3030609620 creator A5071278206 @default.
- W3030609620 date "2013-11-25" @default.
- W3030609620 modified "2023-10-15" @default.
- W3030609620 title "Chinese multiple myeloma patients at high risk benefit more from autologous stem cell transplantation" @default.
- W3030609620 doi "https://doi.org/10.3760/cma.j.issn.1009-9921.2013.11.002" @default.
- W3030609620 hasPublicationYear "2013" @default.
- W3030609620 type Work @default.
- W3030609620 sameAs 3030609620 @default.
- W3030609620 citedByCount "0" @default.
- W3030609620 crossrefType "journal-article" @default.
- W3030609620 hasAuthorship W3030609620A5005131686 @default.
- W3030609620 hasAuthorship W3030609620A5010738973 @default.
- W3030609620 hasAuthorship W3030609620A5015870868 @default.
- W3030609620 hasAuthorship W3030609620A5018889104 @default.
- W3030609620 hasAuthorship W3030609620A5031186378 @default.
- W3030609620 hasAuthorship W3030609620A5036519850 @default.
- W3030609620 hasAuthorship W3030609620A5071278206 @default.
- W3030609620 hasConcept C126322002 @default.
- W3030609620 hasConcept C141071460 @default.
- W3030609620 hasConcept C143998085 @default.
- W3030609620 hasConcept C146357865 @default.
- W3030609620 hasConcept C151730666 @default.
- W3030609620 hasConcept C2776364478 @default.
- W3030609620 hasConcept C2779050716 @default.
- W3030609620 hasConcept C2780739268 @default.
- W3030609620 hasConcept C3019894029 @default.
- W3030609620 hasConcept C71924100 @default.
- W3030609620 hasConcept C86803240 @default.
- W3030609620 hasConceptScore W3030609620C126322002 @default.
- W3030609620 hasConceptScore W3030609620C141071460 @default.
- W3030609620 hasConceptScore W3030609620C143998085 @default.
- W3030609620 hasConceptScore W3030609620C146357865 @default.
- W3030609620 hasConceptScore W3030609620C151730666 @default.
- W3030609620 hasConceptScore W3030609620C2776364478 @default.
- W3030609620 hasConceptScore W3030609620C2779050716 @default.
- W3030609620 hasConceptScore W3030609620C2780739268 @default.
- W3030609620 hasConceptScore W3030609620C3019894029 @default.
- W3030609620 hasConceptScore W3030609620C71924100 @default.
- W3030609620 hasConceptScore W3030609620C86803240 @default.
- W3030609620 hasIssue "11" @default.
- W3030609620 hasLocation W30306096201 @default.
- W3030609620 hasOpenAccess W3030609620 @default.
- W3030609620 hasPrimaryLocation W30306096201 @default.
- W3030609620 hasRelatedWork W2116029073 @default.
- W3030609620 hasRelatedWork W2127283357 @default.
- W3030609620 hasRelatedWork W2135809890 @default.
- W3030609620 hasRelatedWork W2463175221 @default.
- W3030609620 hasRelatedWork W2478224043 @default.
- W3030609620 hasRelatedWork W2494811759 @default.
- W3030609620 hasRelatedWork W2520215469 @default.
- W3030609620 hasRelatedWork W2531192465 @default.
- W3030609620 hasRelatedWork W2544655768 @default.
- W3030609620 hasRelatedWork W2549127713 @default.
- W3030609620 hasRelatedWork W2550446565 @default.
- W3030609620 hasRelatedWork W2568971600 @default.
- W3030609620 hasRelatedWork W2574051972 @default.
- W3030609620 hasRelatedWork W2590211475 @default.
- W3030609620 hasRelatedWork W2921612835 @default.
- W3030609620 hasRelatedWork W2983319734 @default.
- W3030609620 hasRelatedWork W3001740318 @default.
- W3030609620 hasRelatedWork W3002897082 @default.
- W3030609620 hasRelatedWork W3094273986 @default.
- W3030609620 hasRelatedWork W3214514446 @default.
- W3030609620 hasVolume "22" @default.
- W3030609620 isParatext "false" @default.
- W3030609620 isRetracted "false" @default.
- W3030609620 magId "3030609620" @default.
- W3030609620 workType "article" @default.